Toolkit/iRANK cells

iRANK cells

Multi-Component Switch·Research·Since 2024

Also known as: engineered myeloid precursors, inducible, engineered myeloid precursors

Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.

Summary

Inducible, engineered myeloid precursors (iRANK cells) treated with a chemical inducer of dimerization (CID) differentiated into TRAP+ multinucleated OCs and resorbed mineralized tissues in vitro.

Usefulness & Problems

Why this is useful

iRANK cells are engineered myeloid precursors that can be induced to differentiate into osteoclast-like cells and resorb mineralized tissue. In this study they were used as a cell therapy platform for heterotopic ossification.; inducible osteoclast differentiation; cell therapy approach for heterotopic ossification

Source:

iRANK cells are engineered myeloid precursors that can be induced to differentiate into osteoclast-like cells and resorb mineralized tissue. In this study they were used as a cell therapy platform for heterotopic ossification.

Source:

inducible osteoclast differentiation

Source:

cell therapy approach for heterotopic ossification

Problem solved

The platform is presented as a way to generate bone-resorptive cells for treating heterotopic ossification, where current treatments are limited and have high recurrence or complications.; provides a controllable engineered myeloid precursor that can differentiate into osteoclasts; enables bone-resorptive cell delivery for heterotopic ossification regression

Source:

The platform is presented as a way to generate bone-resorptive cells for treating heterotopic ossification, where current treatments are limited and have high recurrence or complications.

Source:

provides a controllable engineered myeloid precursor that can differentiate into osteoclasts

Source:

enables bone-resorptive cell delivery for heterotopic ossification regression

Problem links

enables bone-resorptive cell delivery for heterotopic ossification regression

Literature

The platform is presented as a way to generate bone-resorptive cells for treating heterotopic ossification, where current treatments are limited and have high recurrence or complications.

Source:

The platform is presented as a way to generate bone-resorptive cells for treating heterotopic ossification, where current treatments are limited and have high recurrence or complications.

provides a controllable engineered myeloid precursor that can differentiate into osteoclasts

Literature

The platform is presented as a way to generate bone-resorptive cells for treating heterotopic ossification, where current treatments are limited and have high recurrence or complications.

Source:

The platform is presented as a way to generate bone-resorptive cells for treating heterotopic ossification, where current treatments are limited and have high recurrence or complications.

Published Workflows

Engineered myeloid precursors differentiate into osteoclasts and resorb heterotopic ossification in mice.

2024

Objective: Develop and test an inducible engineered myeloid precursor cell therapy that differentiates into osteoclasts and resorbs heterotopic ossification.

Why it works: The workflow is based on using inducible engineered myeloid precursors that, upon CID treatment, become osteoclast-like cells capable of resorbing mineralized tissue, which is then tested against heterotopic ossification lesions in mice.

differentiation of engineered myeloid precursors into osteoclastsbone resorption by osteoclast-like cellsgenetic engineering of myeloid precursorschemical induction of differentiationin vitro functional testingin vivo therapeutic testing

Stages

  1. 1.
    In vitro inducible differentiation and resorption testing(functional_characterization)

    This stage establishes that the engineered precursor cells can be activated to become functional osteoclast-like cells before in vivo testing.

    Selection: Ability of CID-treated iRANK cells to differentiate into TRAP+ multinucleated osteoclasts and resorb mineralized tissues in vitro

  2. 2.
    In vivo therapeutic evaluation in BMP-2-induced murine heterotopic ossification(in_vivo_validation)

    This stage tests whether the in vitro osteoclast differentiation and resorptive activity translate into therapeutic regression of heterotopic ossification lesions in vivo.

    Selection: Regression of BMP-2-induced murine heterotopic ossification lesions after iRANK cell treatment with systemic CID

  3. 3.
    In vivo marker-based confirmation of delivered-cell differentiation(confirmatory_validation)

    This stage confirms that osteoclasts observed in vivo arose from delivered engineered cells rather than only endogenous cells.

    Selection: Detection of TRAP+, MMP9+, GFP+ osteoclasts indicating differentiation from delivered iRANK cells

Steps

  1. 1.
    Treat iRANK cells with CIDengineered precursor being activated

    Induce the engineered myeloid precursors toward osteoclast differentiation.

    CID treatment is the activating intervention required before assessing whether the engineered cells can differentiate and function as osteoclasts.

  2. 2.
    Assess osteoclast differentiation and mineralized tissue resorption in vitroengineered precursor-derived osteoclast system under test

    Determine whether CID-treated iRANK cells become TRAP+ multinucleated osteoclasts and resorb mineralized tissue.

    Functional in vitro confirmation is performed after induction to establish that the engineered cells have the intended osteoclast phenotype and activity before in vivo testing.

  3. 3.
    Treat BMP-2-induced murine heterotopic ossification lesions with iRANK cells and systemic CIDtherapeutic cell product

    Test whether the engineered precursor platform can regress heterotopic ossification lesions in vivo.

    After in vitro functional evidence, the therapy is evaluated in a disease-relevant mouse model to test translational efficacy.

  4. 4.
    Examine osteoclast markers and GFP to confirm differentiation from delivered iRANK cellsdelivered engineered cell lineage under confirmation

    Confirm that osteoclasts present in vivo derived from delivered iRANK cells.

    This confirmatory analysis follows therapeutic testing to support the mechanism and origin of the cells associated with lesion regression.

Taxonomy & Function

Primary hierarchy

Mechanism Branch

Architecture: A composed arrangement of multiple parts that instantiates one or more mechanisms.

Techniques

No technique tags yet.

Target processes

No target processes tagged yet.

Input: Chemical

Implementation Constraints

cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationimplementation constraint: multi component delivery burdenoperating role: actuatorswitch architecture: multi componentswitch architecture: recruitment

The abstract states that iRANK cells require treatment with a chemical inducer of dimerization, and in vivo use involved concomitant systemic CID administration. The in vivo efficacy test was performed in a BMP-2-induced murine heterotopic ossification model.; requires chemical inducer of dimerization activation; used here in a murine BMP-2-induced heterotopic ossification setting

The abstract does not show that this approach addresses all causes of heterotopic ossification or eliminates the need for external induction. It also does not establish human clinical efficacy.; requires concomitant systemic administration of CID

Validation

Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication

Observations

successMouseapplication demomouse

marker-based in vivo lineage evidence

Inferred from claim c3 during normalization. Many TRAP-positive, MMP9-positive, GFP-positive osteoclasts in vivo indicated differentiation from delivered iRANK cells. Derived from claim c3.

Source:

successMousetherapeutic usemouse

in vivo heterotopic ossification lesion regression

Inferred from claim c2 during normalization. Treatment with iRANK cells plus concomitant systemic CID significantly regressed BMP-2-induced murine heterotopic ossification lesions in vivo. Derived from claim c2.

Source:

lesion regression significance(significantly regressed)

Supporting Sources

Ranked Claims

Claim 1functional activitysupports2024Source 1needs review

iRANK cells treated with a chemical inducer of dimerization differentiated into TRAP-positive multinucleated osteoclasts and resorbed mineralized tissues in vitro.

Claim 2lineage evidencesupports2024Source 1needs review

Many TRAP-positive, MMP9-positive, GFP-positive osteoclasts in vivo indicated differentiation from delivered iRANK cells.

Claim 3therapeutic effectsupports2024Source 1needs review

Treatment with iRANK cells plus concomitant systemic CID significantly regressed BMP-2-induced murine heterotopic ossification lesions in vivo.

lesion regression significance significantly regressed
Claim 4therapeutic rationalesupports2024Source 1needs review

Genetically engineered osteoclasts are presented as a novel cell therapy approach to treat heterotopic ossification.

Approval Evidence

1 source3 linked approval claimsfirst-pass slug irank-cells
Inducible, engineered myeloid precursors (iRANK cells) treated with a chemical inducer of dimerization (CID) differentiated into TRAP+ multinucleated OCs and resorbed mineralized tissues in vitro.

Source:

functional activitysupports

iRANK cells treated with a chemical inducer of dimerization differentiated into TRAP-positive multinucleated osteoclasts and resorbed mineralized tissues in vitro.

Source:

lineage evidencesupports

Many TRAP-positive, MMP9-positive, GFP-positive osteoclasts in vivo indicated differentiation from delivered iRANK cells.

Source:

therapeutic effectsupports

Treatment with iRANK cells plus concomitant systemic CID significantly regressed BMP-2-induced murine heterotopic ossification lesions in vivo.

Source:

Comparisons

Source-stated alternatives

The abstract contrasts this approach with current heterotopic ossification treatments in general, stating that they are limited and have significant complications with high recurrence rates.

Source:

The abstract contrasts this approach with current heterotopic ossification treatments in general, stating that they are limited and have significant complications with high recurrence rates.

Source-backed strengths

differentiated into TRAP+ multinucleated osteoclasts after CID treatment; associated with significant regression of BMP-2-induced murine heterotopic ossification lesions in vivo

Source:

differentiated into TRAP+ multinucleated osteoclasts after CID treatment

Source:

associated with significant regression of BMP-2-induced murine heterotopic ossification lesions in vivo

Compared with CBP/p300 coactivator complex

iRANK cells and CBP/p300 coactivator complex address a similar problem space.

Shared frame: same top-level item type; same primary input modality: chemical

Compared with chGFE3

iRANK cells and chGFE3 address a similar problem space.

Shared frame: same top-level item type; shared mechanisms: heterodimerization; same primary input modality: chemical

Compared with SynSAC

iRANK cells and SynSAC address a similar problem space.

Shared frame: same top-level item type; shared mechanisms: heterodimerization; same primary input modality: chemical

Ranked Citations

  1. 1.
    StructuralSource 1MED2024Claim 1Claim 2Claim 3

    Seeded from load plan for claim c2. Extracted from this source document.